SEARCH

SEARCH BY CITATION

References

  • 1
    Slamon DJ, Clark GM. Amplification of C-ERB-B2 and aggressive breast tumors? Science 1988; 240: 17951798.
  • 2
    de Potter CR. The neu oncogene: more than a prognostic indicator? Hum Pathol 1994; 25: 12641268.
  • 3
    Lupu R, Cardillo M, Harris L, et al. Interaction between ERB-receptors and heregulin in breast cancer tumor progression and drug resistance. Sem Cancer Biol 1995; 6: 135145.
  • 4
    Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the Her-2/neu oncogene. Science 1987; 235: 177182.
  • 5
    Berger MS, Locher GW, Saurer S, et al. Correlation of c-erb B2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 1988; 48: 12381243.
  • 6
    Van de Vivjer MJ, Peterse JL, Mooi WJ, et al. Neu-protein overexpression in breast cancer. N Engl J Med 1988; 319: 12391245.
  • 7
    Heintz NH, Leslie KO, Rogers LA, et al. Amplification of the c-erb B-2 oncogene in prognosis of breast adenocarcinoma. Arch Pathol Lab Med 1990; 114: 160163.
  • 8
    Tsuda H, Hirohashi S, Shimosato Y, et al. Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma. A retrospective analysis of 176 cases. Cancer 1990; 65: 17941800.
  • 9
    Borg A, Tandon AK, Sigurdsson H, et al. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990; 50: 43324337.
  • 10
    Paik S, Hazan R, Fisher ER, et al. Pathologic findings from the nations' surgical adjuvant breast and bowel project: prognostic significance of erb B2 protein overexpression in primary breast cancer. J Clin Oncol 1990; 8: 103112.
  • 11
    Battifora H, Gaffey M, Esteban J, et al. Immunohistochemical assay of neu/c-erb B-2 oncogene product in paraffin-embedded tissues in early breast cancer: Retrospective follow-up study of 245 stage I and II cases. Modern Pathol 1991; 4: 466474.
  • 12
    Kallioniemi OP, Holli K, Visakorpi T, et al. Association of C-erb B2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 1991; 49: 650655.
  • 13
    Clark GM, McGuire WL. Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 1991; 51: 944948.
  • 14
    Lovekin C, Ellis IO, Locker A, et al. C-erb B2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 1991; 63: 439443.
  • 15
    McCann AH, DeDervan TA, O'Regan M, et al. Prognostic significance of C-erb B2 and estrogen receptor status in human breast cancer. Cancer Res 1991; 51: 32963303.
  • 16
    Dykens R, Corbett IP, Henry J, et al. Long term survival in breast cancer related to overexpression of the C-erb B2 oncoprotein: an immunohistochemical study using monoclonal antibody NCL-CB11. J Pathol 1991; 163: 105110.
  • 17
    Rilke F, Colnaghi MI, Cascinelli N, et al. Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 1991; 49: 4449.
  • 18
    Winstanley J, Cooke T, Murray GD, et al. The long term prognostic significance of C-erb B2 in primary breast cancer. Br J Cancer 1991; 63: 447450.
  • 19
    O'Reilly SM, Barnes DM, Camplejohn RS, et al. The relationship between C-erb B2 expression, and s-phase fraction in prognosis in breast cancer. Br J Cancer 1991; 63: 444446.
  • 20
    Paterson MC, Dietrich KD, Danyluk J, et al. Correlation between C-erb B2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res 1991; 51: 556567.
  • 21
    Toikkanen S, Helin H, Isola J, et al. Prognostic significance of Her-2 oncoprotein expression in breast cancer: a 30-year follow up. J Clin Oncol 1992; 10: 10441048.
  • 22
    Molina R, Ciocca DR, Candon AK, et al. Expression of HER-2/neu oncoprotein in breast cancer: a comparison of immunohistochemical and western blot techniques. Anticancer Res 1992; 12: 19651991.
  • 23
    Noguchi M, Koyasaki M, Ohta N, et al. c-erb B-2 oncoprotein expression versus internal mammary lymph node metastases as additional prognostic factors in patients with axillary lymph node-positive breast cancer. Cancer 1992; 69: 29532960.
  • 24
    Allred DC, Clark GM, Tandon AK, et al. HER-2/neu node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in-situ carcinoma. J Clin Oncol 1992; 10: 599605.
  • 25
    Babiak J, Hugh J, Poppeme S. Significance of c-erb B-2 amplification in DNA aneuploidy. Analysis in 78 patients with node-negative breast cancer. Cancer 1992; 70: 770776.
  • 26
    Tiwari RK, Borgen PI, Wong GY, et al. HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis. Anticancer Res 1992; 12: 419426.
  • 27
    Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of C-erb B2 expression in breast cancer. J Clin Oncol 1992; 10: 10491056.
  • 28
    Bianchi S, Paglierani M, Zampi G, et al. Prognostic significance of C-erb B2 expression in node negative breast cancer. Br J Cancer 1993; 67: 625629.
  • 29
    Press MF, Pike MC, Chazin VR, et al. Her-2/neu expression in node-negative breast cancer: direct tissue quantification by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 1993; 53: 49604970.
  • 30
    Seshadri R, Firgaira FA, Horsfall DJ, et al. Clinical significance of Her-2/neu oncogene amplification in primary breast cancer. J Clin Oncol 1993; 11: 19361942.
  • 31
    Descotes F, Pavy J-J, Adessi GL. Human breast cancer: correlation study between Her-2/neu amplification and prognostic factors in an unselected population. Anticancer Res 1993; 13: 119124.
  • 32
    Giai M, Roagna R, Ponzone R, et al. Prognostic and predictive relevance of C-erb B2 and ras expression in node-positive and negative breast cancer. Anticancer Res 1994; 14: 14411450.
  • 33
    Muss HB, Thor AD, Berry DA, et al. Cerb-B2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994; 330: 12601266.
  • 34
    Tetu B, Brisson J. Prognostic significance of Her-2/neu oncogene expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy. Cancer 1994; 73: 23592365.
  • 35
    Hartmann LC, Ingle JN, Wold LE, et al. Prognostic value of CerbB2 overexpression in axillary lymph node-positive breast cancer. Results from a randomized adjuvant treatment protocol. Cancer 1994; 74: 29562963.
  • 36
    Jacquemier J, Penault-Llorca P, Viens P, et al. Breast cancer response to adjuvant chemotherapy in correlation with erb B2 and p53 expression. Anticancer Res 1994; 14: 27732778.
  • 37
    Marks JR, Humphrey PA, Wu K at al. Overexpression of p53 and Her-2/neu proteins as prognostic markers in early stage breast cancer. Ann Surg 1994; 219: 332341.
  • 38
    Rosen PP, Lesser ML, Arroyo CD, et al. Immunohistochemical detection of Her-2/neu expression in patients with axillary lymph node-negative breast carcinoma. A study of epidemiologic risk factors, histologic features and prognosis. Cancer 1995; 75: 13201326.
  • 39
    Quenel N, Wafflart J, Bonichon F, et al. The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases. Breast Cancer Res Treat 1995; 35: 283291.
  • 40
    Sundblad AS, Pellicer EM, Ricci L. Carcinoembryonic expression in stages I and II breast cancer; its relationship with clinicopathologic factors. Hum Pathol 1996; 27: 297300.
  • 41
    O'Malley FP, Saad Z, Kerkvliet N, et al. The predictive power of semiquantitative immunohistochemical assessment of p53 and C-erbB2 in lymph node-negative breast cancer. Hum Pathol 1996; 27: 955963.
  • 42
    Hieken TJ, Mehta RR, Shilkaitis A, et al. Her-2/neu and p53 expression in breast cancer: valid prognostic markers when assessed by direct immunoassay, but not by immunochemistry. Proc Annu Meet Am Soc Clin Oncol 1996; 15:113a
  • 43
    Xing W-R, Gilchrist KW, Harris CP, et al. FISH detection of HER-2/neu oncogene amplification in early onset breast cancer. Breast Cancer Res Treat 1996; 39: 203212.
  • 44
    Dittadi R, Brazzale A, Pappagallo G, et al. ErbB2 assay in breast cancer: possibly improved clinical information using a quantitative method. Anticancer Res 1997; 17: 12451247.
  • 45
    Fernandez-Acenero MJ, Farina Gonzalez J, Arangoncillo Ballesteros P. Immunohistochemical expression of p53 and c-erbB-2 in breast carcinoma: relation with epidemiologic factors, histologic features and prognosis. Gen Diagn Pathol 1997; 142: 289296.
  • 46
    Eissa S, Khalifa A, el-Gharib A, et al. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for short-term prognosis in breast cancer. Anticancer Res 1997; 17: 30913097.
  • 47
    Charpin C, Garcia S, Bouvier C, et al. c-erbB-2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients' overall and disease-free survival. Br J Cancer 1997; 75: 16671673.
  • 48
    Press MJ, Bernstein L, Thomas PA, et al. Her-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997; 15: 28942904.
  • 49
    Ross JS, Muraca PJ, Jaffe D, et al. Multivariate analysis of prognostic factors in lymph node negative breast cancer. Mod Pathol 1998; 11:26a
  • 50
    Depowski PL, Brien TP, Sheehan CE, et al. Prognostic significance of p34cdc2 cyclin dependent kinase and MIB1 overexpression, and HER-2/neu gene amplification detected by fluorescence in-situ hybridization in breast cancer. Mod Pathol 1998; 11:18A
  • 51
    Page DL. Prognosis and breast cancer. Recognition of lethal and favorable prognostic types. Am J Surg Pathol 1991; 15: 334349.
  • 52
    Porter-Jordan K, Lippman ME. Overview of the biologic markers in breast cancer. Hematol Oncol Clin North Am 1994; 8: 73100.
  • 53
    McGuire WL, Tandon AK, Allred DC, et al. How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst 1990; 82: 10061015.
  • 54
    Pauletti G, Godolphin W, Press MF, et al. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996; 13: 6372.
  • 55
    Sauter G, Feichter G, Torhorst J, et al. Fluorescence in-situ hybridization for detecting ERBB-2 amplification in breast tumor fine needle aspiration biopsies. Acta Cytol 1996; 40: 164173.
  • 56
    Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11: 155168.
  • 57
    Jacobs TW, Prioleau JE, Stillman IE, et al. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J Natl Cancer Inst 1996; 88: 10541059.
  • 58
    Penault-Llorca F, Adelaide J, Houvenaeghel G, et al. Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation. J Pathol 1994; 173: 6575.
  • 59
    Busmanis I, Feleppa F, Jones A, et al. Analysis of C-erb B2 expression using a panel of six commercially available antibodies. Pathol 1994; 26: 261267.
  • 60
    Press MF, Hung G, Godolphin W, et al. Sensitivity of Her-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994; 54: 27712777.
  • 61
    vanDiest PJ, vanDam P, Henzen-Logmans SC, et al. A scoring system for immunohistochemical staining: consensus report of the Task Force for Basic Research of the EORTC-GCGC. J Clin Pathol 1997; 50: 801804.
  • 62
    Lodato RF, Maguire HC, Greene MI, et al. Immunohistochemical evaluation of cerb B2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast. Mod Pathol 1990; 3: 449454.
  • 63
    Allred DC, Clark GM, Molina R, et al. Overexpression of Her-2/neu and its relationship with other prognostic factors changed during progression of in-situ to invasive breast cancer. Hum Pathol 1992; 23: 974979.
  • 64
    Zafrani B, Leroyer A, Fourquet A, et al. Mammographically-detected ductal in-situ carcinoma of the breast analyzed with a new classification. Sem Diagn Pathol 1994; 11: 208214.
  • 65
    Brower FT, Ahmed S, Tartter P, et al. Prognostic variables in invasive breast cancer: Contribution of comedo versus non-comedo in-situ component. Ann Surg Oncol 1995; 2: 440444.
  • 66
    Leal CB, Schmitt FC, Bento NJ, et al. Ductal carcinoma in-situ of the breast. Histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53 and C erb B-2 protein. Cancer 1995; 75: 21232131.
  • 67
    Bobrow WLG, Happerfield LC, Gregory WM, et al. Ductal carcinoma in-situ: assessment of necrosis in nuclear morphology and their association with biological markers. J Pathol 1995; 176: 333341.
  • 68
    DePotter CR, Schelhout AM, Verbeeck P, et al. neu overexpression correlates with extent of disease in large cell ductal in situ carcinoma of the breast. Hum Pathol 1995; 26: 601606.
  • 69
    Inaji H, Koyama H, Motomura K, et al. Differential distribution of erb B2 and pS2 proteins in ductal carcinoma in-situ of the breast. Breast Cancer Res Treat 1996; 37: 8992.
  • 70
    Albonico G, Querzoli P, Ferretti S, et al. Biophenotypes of breast carcinoma in-situ defined by image analysis of biological parameters. Pathol Res Pract 1996; 192: 117123.
  • 71
    Bose S, Lesser ML, Norton L, et al. Immunophenotype of intraductal carcinoma. Arch Pathol Lab Med 1996; 120: 8185.
  • 72
    Moreno A, Lloveras B, Figueras A, et al. Ductal carcinoma in-situ of the breast: Correlation between histologic classification and biologic markers. Mod Pathol 1997; 10: 10881092.
  • 73
    Mack L, Kerkzelit N, Doig G, et al. Relationship of a new histological categorization of ductal carcinoma in-situ of the breast with size and the immunohistochemical expression of p53, C-erb B2, bcl2 and ki-67. Hum Pathol 1997; 28: 974979.
  • 74
    Porter PL, Garcia R, Moe R, et al. cerb B2 oncogene protein in in-situ and invasive lobular breast neoplasia. Cancer 1991; 68: 331334.
  • 75
    Wolber RA, DuPuis BA, Wick MR. Expression of cerb B2 oncoprotein in mammary and extramammary Paget's disease. Am J Clin Pathol 1991; 96: 243247.
  • 76
    Lilleng R, Hagmar BM, Nesland JM. cerb B2 protein and neuroendocrine expression in intraductal carcinomas of the breast. Mod Pathol 1992; 5: 4147.
  • 77
    Yeh I-T, Keykhah S, Selig AM, et al. Expression of erb B2 gene in the benign and proliferative breast tissue. Surg Pathol 1993; 5: 109120.
  • 78
    Hanna W, Kahn HJ, Andrulis I, et al. Distribution and patterns of staining of neu oncogene product in benign and malignant breast diseases. Mod Pathol 1990; 3: 455461.
  • 79
    Odagiri E, Kanda N, Jibiki K, et al. Reduction of telomeric-linked cerb B2 gene amplification in human breast cancer, fibroadenoma, and gynecomastia. Relationship to histologic grade and clinical parameters. Cancer 1994; 73: 29782984.
  • 80
    Gattuso P, Reddy VB, Green LK, et al. Prognostic factors for carcinoma of the male breast. Int J Surg Pathol 1995; 2: 199206.
  • 81
    Joshi MG, Lee AK, Loda M, et al. Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome. Cancer 1996; 77: 490498.
  • 82
    Willsher PC, Leach IH, Ellis IO, et al. Male breast cancer: pathological and immunohistochemical features. Anticancer Res 1997; 17: 23352338.
  • 83
    Bines J, Goss B, Hussong J, et al. C-erb and p53 overexpression as predictors of survival in patients with male breast cancer. Proc Ann Assoc Clin Oncol 1997; 16:558a
  • 84
    Bruce DM, Heyes SD, Payne S, et al. Male breast cancer: clinico-pathological features, immunocytochemical characteristics and prognosis. Eur J Surg Oncol 1996; 22: 4246.
  • 85
    Dawson PJ, Paine TM, Wolman SR. Immunocytochemical characterization of male breast cancer. Mod Pathol 1992; 5: 621625.
  • 86
    Wright C, Nicholson S, Angus B, et al. Relationship between C-ERBB 2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 1992; 65: 118121.
  • 87
    Leitzel K, Teramoto Y, Konrad K, et al. Elevated serum C-erb B2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 1995; 13: 11291135.
  • 88
    Berns EM, Foekens JA, vanStaveren IL, et al. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene 1995; 159: 1118.
  • 89
    Stahl O, Sullivan S, Wingren S, et al. C-erbB2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer 1995; 31:2185a2190a.
  • 90
    Archer SG, Eliopoulis SA, Spandidos D, et al. Expression of ras p21, p53 and C-erb B2 in advanced breast cancer and response to line hormonal therapy. Br J Cancer 1995; 72: 12591266.
  • 91
    Yu D, Liu B, Tan M, et al. Overexpression of cerbB2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene 1996; 13: 13591365.
  • 92
    Carlomagno C, Perrone F, Gallo C, et al. CerbB2 overexpression decreases the benefit of adjuvant Tamoxifen in early-stage breast cancer without ancillary lymph node metastases. J Clin Oncol 1996; 14: 27022708.
  • 93
    Haffty BG, Brown F, Carter D, et al. Evaluation of HER-2/neu oncoprotein expression as a prognostic indicator of local recurrence in conservatively treated breast cancer: a case-control study. Int J Rad Oncol Biol Phys 1996; 35: 751757.
  • 94
    Revillion F, Hebbar M, Boneterre J, et al. Plasma CerbB2 concentrations in relations to chemotherapy in breast cancer patients. Eur J Cancer 1996; 32:231a234a.
  • 95
    Baselga J, Seidman AD, Rosen PP, et al. HER-2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology 1997; 11: 4348.
  • 96
    Pegram MD, Finn RS, Arzoo K, et al. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 1997; 15: 537547.
  • 97
    Newby JC, Johnston SRD, Smith IE, et al. Expression of epidermal growth factor receptor and C-erb B2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res 1997; 3: 16431651.
  • 98
    Burke HB, Hoang A, Iglehart JD, et al. Predicting response to adjuvant and radiation therapy in patients with early stage breast carcinoma. Cancer 1998; 82: 874877.
  • 99
    Yamauchi H, O'Neill A, Gelman R, et al. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 1997; 15: 25182525.
  • 100
    Elledge RM, Green S, Ciocca D, et al. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group study. Clin Cancer Res 1998; 4: 712.
  • 101
    Bianco AR, De Laurentiis M, Carlomagno C, et al. 20 year update of the Naples Gun trial of adjuvant breast cancer therapy: eveidence of interaction between c-erb-B2 expression and tamoxifen efficacy. Proc Am Soc Clin Oncol 1998; 17:97a
  • 102
    Ravdin PM, Green S, Albain V, et al. Initial report of the SWOG biological correlative study of c-ERBB2 expression as a predictor of outcome in a trial comparing adjuvant CAF with Tamoxifen alone. Proc Am Soc Clin Oncol 1998; 17:97a
  • 103
    Isola JJ, Holli K, Oksa H, et al. Elevated erb B-2 oncoprotein levels in preoperative and follow-up serum samples defined in aggressive course in patients with breast cancer. Cancer 1994; 73: 652658.
  • 104
    Kandl H, Seymour L, Bezwoda WR. Soluble c-erb B-2 fragments in serum correlates with disease stage and predicts more shortened survival in patients with early-stage and advanced breast cancer. Br J Cancer 1994; 70:
  • 105
    Wu JT, Astill ME, Gagon SD, et al. Measurement of C-erb B2 proteins in sera from patients with carcinomas and in breast tumor tissue cytosols: correlation with serum tumor markers and membrane-bound oncoproteins. J Clin Lab Anal 1995; 9: 151165.
  • 106
    Andersen TI, Paus E, Nesland JM, et al. Detection of C-erb B2 related proteins in sera from breast cancer patients. Relationship to ERBB2 gene amplification and Cerb B2 protein overexpression in tumour. Acta Oncol 1995; 34: 499504.
  • 107
    Volas GH, Leitzel K, Teramoto Y, et al. Serial serum C-erbB-2 levels in patients with breast carcinoma. Cancer 1996; 78: 267272.
  • 108
    Molina R, Jo J, Vanon G, et al. Utility of cerbB2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA15.3. Br J Cancer 1996; 74: 11261131.
  • 109
    Willsher PC, Beaver J, Pinder S, et al. Prognostic significance of serum CerbB2 protein in breast cancer patients. Breast Cancer Res Treat 1996; 40: 251255.
  • 110
    Fehm T, Maimonis P, Wetz S, et al. Influence of circulating C-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients. Breast Cancer Res Treat 1997; 43: 8795.
  • 111
    Mansour OA, Zekri AR, Harvey J, et al. Tissue in serum CerbB2 and tissue EGFR in breast carcinoma: three years follow-up. Anti Cancer Res 1997; 17: 31013106.
  • 112
    Shepard HM, Lewis GD, Sarup JC, et al. Monoclonal antibody therapy of human cancer: taking the Her-2 proto-oncogene to the clinic. J Clin Immunol 1991; 11: 117127.
  • 113
    Zhang L, Chang C, Bacus SS, et al. Suppressed transformation and induced differentiation of Her-2/neu—overexpressing breast cancer cells by emodin. Cancer Res 1995; 55: 38903896.
  • 114
    Valone FH, Kaufman PA, Guyre PM, et al. Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J Clin Oncol 1995; 13: 22812292.
  • 115
    Jinno H, Ueda M, Enomoto K, et al. Effectiveness of an Adriamycin immunoconjugate that recognizes the CerbB2 product on breast cancer cell lines. Surg Today 1996; 26: 501507.
  • 116
    Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti p185 Her-2 monoclonal antibody in patients with Her-2/neu overexpressing metastatic breast cancer. J Clin Oncol 1996; 14: 737744.
  • 117
    Liu X, Pogo BG. Inhibition of erbB2 positive breast cancer cell growth by erbB2 antisense oligonucleotides. Antisense Nucleic Acid Drug Devel 1996; 6: 916.
  • 118
    Wright M, Grim J, Deshane J, et al. An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2. Gene Ther 1997; 4: 317322.
  • 119
    Heijnen IA, Buhring HJ, Deo YN, et al. The clinical studies with Fc (Gamma) R by specific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpression in breast cancer. Cancer Res 1997; 57: 696701.
  • 120
    Witters LM, Kumar R, Chinchilli ZM, et al. Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody. Breast Cancer Res Treat 1997; 42: 15.
  • 121
    Cobleigh MA, Vogel CL, Tripathy NJ, et al. Efficacy and safety of Herceptin® (humanized anti-human HER-2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 1998; 17:97a
  • 122
    Slamon D, Leyland-Jones B, Shak S, et al. Addition of Herceptin® (humanized anti HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: a randomized, multinational controlled phase III trial. Proc Am Soc Clin Oncol 1998; 17:98a
  • 123
    Brossart P, Stuhler J, Flad P, et al. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res 1998; 58: 732736.
  • 124
    Disis ML, Grabstein KH, Cheaver MA. HER-2/neu peptide vaccines elicit T cell immunity to the HER-2/neu protein in patients with breast and ovarian cancer. Proc Am Soc Clin Oncol 1998; 17:97a
  • 125
    Allan SM, Dean CJ, Eccles S, et al. Clinicoradioimmunolocalization with a rat monoclonal antibody directed against C-erb B2. Cell Biophys 1994; 24: 9398.